Apotex Loses Appeal In Risperdal Patent Fight
A federal appeals court on Thursday upheld a district judge's decision to dismiss Apotex Inc.'s counterclaims of noninfringement in connection with a patent fight over Johnson & Johnson subsidiary Janssen's anti-psychotic...To view the full article, register now.
Already a subscriber? Click here to view full article